Ha habido 50 transacciones internas recientes registradas para Matinas BioPharma Holdings, Inc. (MTNB), incluyendo 40 compras y 0 ventas. El total de compras internas fue valorado en $7.11M y el total de ventas internas en RSU Award.
Internos destacados con actividad reciente incluyen Neugeboren Edward, D An Evelyn, Smith Robin L. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — MTNB
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2025-04-30 |
Neugeboren Edward |
Director |
Concesión de RSU |
11,600 |
$0.59 |
$6.84K |
11,600 |
| 2025-04-30 |
D An Evelyn |
Director |
Concesión de RSU |
11,600 |
$0.59 |
$6.84K |
11,600 |
| 2025-04-30 |
Smith Robin L |
Director |
Concesión de RSU |
11,600 |
$0.59 |
$6.84K |
11,600 |
| 2025-04-30 |
Murphy Keith |
Director |
Concesión de RSU |
11,600 |
$0.59 |
$6.84K |
11,600 |
| 2025-04-30 |
Jabbour Jerome D |
President and CEO |
Concesión de RSU |
70,100 |
$0.59 |
$41.36K |
70,100 |
| 2025-04-08 |
Eide Robert J |
10 Percent Owner |
Compra Informativa |
492 |
$0.59 |
$288.31 |
984 |
| 2025-04-08 |
Pembroke & Partners Llc |
10 Percent Owner |
Compra Informativa |
492 |
$0.59 |
$288.31 |
984 |
| 2025-04-08 |
Sanitam Partners Llc |
10 Percent Owner |
Compra Informativa |
703 |
$0.59 |
$411.96 |
1,406 |
| 2025-03-11 |
Neugeboren Edward |
Director |
Desconocido |
- |
- |
- |
- |
| 2025-03-11 |
Murphy Keith |
Director |
Desconocido |
- |
- |
- |
- |
| 2025-02-13 |
Smith Robin L |
Director |
Desconocido |
- |
- |
- |
- |
| 2025-02-13 |
Pembroke & Partners Llc |
10 Percent Owner |
Desconocido |
839,591 |
- |
- |
- |
| 2025-02-13 |
Sanitam Partners Llc |
10 Percent Owner |
Desconocido |
2,399,318 |
- |
- |
- |
| 2025-02-13 |
Eide Robert J |
10 Percent Owner |
Desconocido |
839,591 |
- |
- |
- |
| 2025-02-13 |
Stern Adam K |
10 Percent Owner |
Desconocido |
4,798,636 |
- |
- |
- |
| 2025-02-05 |
D An Evelyn |
Director |
Desconocido |
- |
- |
- |
- |
| 2023-12-15 |
Jabbour Jerome D |
President and CEO |
Concesión de RSU |
3,500,000 |
$0.25 |
$864.5K |
3,500,000 |
| 2023-12-15 |
Matkovits Theresa |
Chief Development Officer |
Concesión de RSU |
1,300,000 |
$0.25 |
$321.1K |
1,300,000 |
| 2023-12-15 |
Kucinski Keith A |
Chief Financial Officer |
Concesión de RSU |
1,000,000 |
$0.25 |
$247K |
1,000,000 |
| 2023-12-15 |
Ferguson James J. Iii |
Chief Medical Officer |
Concesión de RSU |
1,200,000 |
$0.25 |
$296.4K |
1,200,000 |
| 2023-12-15 |
Liu Hui |
Chief Technology Officer |
Concesión de RSU |
1,000,000 |
$0.25 |
$247K |
1,000,000 |
| 2023-12-15 |
Hoover Thomas |
Chief Business Officer |
Concesión de RSU |
1,000,000 |
$0.25 |
$247K |
1,000,000 |
| 2023-11-01 |
Wikler Matthew |
Director |
Concesión de RSU |
437,244 |
$0.21 |
$91.3K |
437,244 |
| 2023-11-01 |
Conrad Herbert J |
Director |
Concesión de RSU |
437,244 |
$0.21 |
$91.3K |
437,244 |
| 2023-11-01 |
Giordano Natasha |
Director |
Concesión de RSU |
437,244 |
$0.21 |
$91.3K |
437,244 |
| 2023-11-01 |
Scibetta James S |
Director |
Concesión de RSU |
437,244 |
$0.21 |
$91.3K |
437,244 |
| 2023-11-01 |
Ende Eric J |
Director |
Concesión de RSU |
437,244 |
$0.21 |
$91.3K |
437,244 |
| 2023-11-01 |
Corzo Kathryn Penkus |
Director |
Concesión de RSU |
437,244 |
$0.21 |
$91.3K |
437,244 |
| 2022-12-20 |
Jabbour Jerome D |
President and CEO |
Concesión de RSU |
1,988,300 |
- |
- |
1,988,300 |
| 2022-12-20 |
Matkovits Theresa |
Chief Development Officer |
Concesión de RSU |
625,000 |
- |
- |
625,000 |
| 2022-12-20 |
Kucinski Keith A |
Chief Financial Officer |
Concesión de RSU |
625,000 |
- |
- |
625,000 |
| 2022-12-20 |
Ferguson James J. Iii |
Chief Medical Officer |
Concesión de RSU |
625,000 |
- |
- |
625,000 |
| 2022-12-20 |
Liu Hui |
Chief Technology Officer |
Concesión de RSU |
625,000 |
- |
- |
625,000 |
| 2022-12-20 |
Hoover Thomas |
Chief Business Officer |
Concesión de RSU |
475,000 |
- |
- |
475,000 |
| 2022-11-14 |
Wikler Matthew |
Director |
Concesión de RSU |
142,657 |
- |
- |
142,657 |
| 2022-11-14 |
Conrad Herbert J |
Director |
Concesión de RSU |
142,657 |
- |
- |
142,657 |
| 2022-11-14 |
Giordano Natasha |
Director |
Concesión de RSU |
142,657 |
- |
- |
142,657 |
| 2022-11-14 |
Scibetta James S |
Director |
Concesión de RSU |
142,657 |
- |
- |
142,657 |
| 2022-11-14 |
Ende Eric J |
Director |
Concesión de RSU |
142,657 |
- |
- |
142,657 |
| 2022-11-14 |
Corzo Kathryn Penkus |
Director |
Concesión de RSU |
142,657 |
- |
- |
142,657 |
| 2022-06-22 |
Conrad Herbert J |
Director |
Donación (Otorgada) |
1,358,122 |
- |
- |
- |
| 2021-12-31 |
Wikler Matthew |
Director |
Concesión de RSU |
7,859 |
- |
- |
290,472 |
| 2021-12-14 |
Mannino Raphael J |
Chief Scientific Officer |
Concesión de RSU |
275,000 |
$0.92 |
$253K |
275,000 |
| 2021-12-14 |
Jabbour Jerome D |
President and CEO |
Concesión de RSU |
1,658,100 |
$0.92 |
$1.53M |
1,658,100 |
| 2021-12-14 |
Matkovits Theresa |
Chief Development Officer |
Concesión de RSU |
500,000 |
$0.92 |
$460K |
500,000 |
| 2021-12-14 |
Kucinski Keith A |
Chief Financial Officer |
Concesión de RSU |
500,000 |
$0.92 |
$460K |
500,000 |
| 2021-12-14 |
Ferguson James J. Iii |
Chief Medical Officer |
Concesión de RSU |
587,600 |
$0.92 |
$540.59K |
587,600 |
| 2021-12-14 |
Hui Liu |
Chief Technology Officer |
Concesión de RSU |
275,000 |
$0.92 |
$253K |
275,000 |
| 2021-12-14 |
Hoover Thomas |
Chief Business Officer |
Concesión de RSU |
850,000 |
$0.92 |
$782K |
850,000 |
| 2021-12-06 |
Hoover Thomas |
Officer |
Desconocido |
- |
- |
- |
- |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento